

Olivier Huillard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2281399/publications.pdf>

Version: 2024-02-01

63
papers

1,267
citations

471509

17
h-index

395702

33
g-index

69
all docs

69
docs citations

69
times ranked

2078
citing authors

#	ARTICLE	IF	CITATIONS
1	Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. <i>British Journal of Cancer</i> , 2013, 108, 1034-1041.	6.4	204
2	Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. <i>Targeted Oncology</i> , 2011, 6, 253-258.	3.6	117
3	Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. <i>Thyroid</i> , 2018, 28, 72-78.	4.5	89
4	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy, <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1139-1147.	4.7	74
5	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	2.6	73
6	Nivolumab, nivolumab+ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 612-624.	10.7	66
7	Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. <i>European Journal of Cancer</i> , 2017, 72, 54-61.	2.8	54
8	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2801-2811.	4.3	54
9	Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 1686-1687.	27.0	43
10	Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 785-794.	3.3	31
11	Resting energy expenditure in the risk assessment of anticancer treatments. <i>Clinical Nutrition</i> , 2018, 37, 558-565.	5.0	25
12	Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. <i>European Journal of Cancer</i> , 2018, 105, 10-18.	2.8	23
13	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 98-107.	1.9	22
14	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	2.6	20
15	Restoring Radioiodine Uptake in BRAF V600E-Mutated Papillary Thyroid Cancer. <i>Journal of the Endocrine Society</i> , 2017, 1, 285-287.	0.2	20
16	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1433-1444.	3.3	19
17	Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. <i>European Journal of Cancer</i> , 2020, 136, 76-83.	2.8	19
18	Redifferentiating Effect of Larotrectinib in NTRK-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	4.5	19

#	ARTICLE	IF	CITATIONS
19	Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study. <i>Cancer</i> , 2018, 124, 3044-3051.	4.1	17
20	Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience. <i>Frontiers in Surgery</i> , 2018, 5, 58.	1.4	16
21	Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 663-673.	2.4	15
22	A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 989, 86-90.	2.3	15
23	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	4.5	15
24	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 155-160.	1.9	13
25	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	2.3	12
26	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 295-303.e3.	1.9	12
27	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	2.8	12
28	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	3.7	12
29	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. <i>Pharmacological Research</i> , 2018, 136, 56-61.	7.1	11
30	Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 1603-1604.	4.5	10
31	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision-Making. <i>Oncologist</i> , 2015, 20, e26.	3.7	9
32	Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 673-687.	4.1	7
33	Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1033-1039.	2.3	7
34	A Real-Life Experience of Bevacizumab in Elderly Women With Advanced Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1196-1200.	2.5	7
35	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e362-e368.	1.9	7
36	Negative Trials for Foreseeable Safety Reasons in Advanced Hepatocellular Carcinoma: How Long Are We Going to Take Lightly Pharmacokinetics of Tyrosine Kinase Inhibitors?. <i>Journal of Clinical Oncology</i> , 2015, 33, 2484-2485.	1.6	6

#	ARTICLE	IF	CITATIONS
37	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 554-562.	1.9	6
38	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. <i>Oncologist</i> , 2014, 19, e3.	3.7	5
39	Sorafenib for patients with differentiated thyroid cancer. <i>Lancet, The</i> , 2015, 385, 227.	13.7	5
40	Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis. <i>JAMA Oncology</i> , 2017, 3, 565.	7.1	5
41	Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 582-582.	1.6	4
42	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib Letter. <i>Clinical Cancer Research</i> , 2015, 21, 5639-5639.	7.0	3
43	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. <i>Lancet Oncology, The</i> , 2016, 17, e468.	10.7	3
44	Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely. <i>European Journal of Cancer</i> , 2020, 135, 51.	2.8	3
45	Angiotensin System Inhibitors in Renal Cell Carcinoma Letter. <i>Clinical Cancer Research</i> , 2016, 22, 524-524.	7.0	2
46	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e493-e495.	1.9	2
47	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.10.006 . <i>European Urology</i> , 2021, 79, e112.	1.9	2
48	Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. <i>Cancers</i> , 2022, 14, 3214.	3.7	2
49	A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. <i>Therapeutics and Clinical Risk Management</i> , 0, Volume 18, 683-698.	2.0	2
50	RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2019, 111, 335-336.	6.3	1
51	Management of Cancer Cachexia: ASCO Guideline Time to Address the Elephant in the Room. <i>Journal of Clinical Oncology</i> , 2020, 38, 3819-3819.	1.6	1
52	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	1.9	1
53	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 170-170.	1.6	1
54	Goals and aggressiveness of care in metastatic lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10026-10026.	1.6	1

#	ARTICLE	IF	CITATIONS
55	How should we manage bevacizumab toxicity in lung cancer patients?. Lung Cancer Management, 2014, 3, 355-363.	1.5	0
56	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients.. Journal of Clinical Oncology, 2014, 32, 9551-9551.	1.6	0
57	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20523-e20523.	1.6	0
58	Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients.. Journal of Clinical Oncology, 2015, 33, 5041-5041.	1.6	0
59	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
60	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0
61	Aggressiveness of care at the end of life in patients with localized and advanced bladder cancer.. Journal of Clinical Oncology, 2016, 34, 10029-10029.	1.6	0
62	Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.. Journal of Clinical Oncology, 2017, 35, e17594-e17594.	1.6	0
63	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0